Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations

Tepotinib (Tepmetko, Merck) is indicated for 'the treatment of adult patients with advanced non-small-cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations'.

The dosage schedule is available in the summary of product characteristics for tepotinib.

The list price is £7,200 for 60×225‑mg tablets of tepotinib (as hydrochloride hydrate). The company has a commercial arrangement. This makes tepotinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.